Clinical pharmacokinetics and pharmacodynamics of tigecycline

Clinical Pharmacokinetics

Volumn 48, Issue 9, 2009, Pages 575-584

  Barbour, April ^a   Schmidt, Stephan ^a   Ma, Benjamin ^a   Schiefelbein, Lars ^a   Rand, Kenneth H ^b   Burkhardt, Olaf ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DIGOXIN; GLYCOPROTEIN P; KETOLIDE; MACROLIDE; ONDANSETRON; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE;

EID: 69849106583     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317100-000000000-00000     Document Type: Review

References (76)

1. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005 Jul; 56 (1): 20-51
2. Connell SR, Tracz DM, Nierhaus KH, et al. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3675-81
3. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999 Apr; 43 (4): 738-44
4. Wilcox MH. Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect (Larchmt) 2006 Feb; 7 (1): 69-80
5. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new gly-cylcycline, GAR-936 tested against 1, 203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000 Jan; 36 (1): 19-36
6. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupris-tin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001 Sep; 45 (9): 2604-8
7. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005 Jul; 52 (3): 173-9
8. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008 Apr; 60 (4): 421-7
9. Tygacil® (tigecycline) for injection: US prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals Inc., 2009 Apr [online]. Available from URL: http://www. wyeth. com/hcp/tygacil/prescribing [Accessed 2009 Aug 6]
10. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005 Jan; 49 (1): 220-9
11. Conte Jr JE, Golden JA, Kelly MG, et al. Steady-state serum and in-trapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005 Jun; 25 (6): 523-9
12. Ong CT, Babalola CP, Nightingale CH, et al. Penetration, efflux and in-tracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005 Sep; 56 (3): 498-501
13. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005 Apr; 49 (4): 1629-32
14. Zimmerman JJ, Harper DM, Matschke K, et al. Absence of an interaction between tigecycline and digoxin in healthy men. Pharmacotherapy 2007 Jun; 27 (6): 835-44
15. Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005 Sep 1; 41 Suppl. 5: S333-40
16. Muralidharan G, Fruncillo RJ, Micalizzi M, et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005 Apr; 49 (4): 1656-9
17. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus. 48th Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; 2008 Oct 25-28; Washington, DC
18. Chin TF, Lach JL. Drug diffusion and bioavailability: tetracycline metallic chelation. Am J Hosp Pharm 1975 Jun; 32 (6): 625-9
19. Gabler WL. Fluxes and accumulation of tetracyclines by human blood cells. Res Commun Chem Pathol Pharmacol 1991 Apr; 72 (1): 39-51
20. Odenholt I, Lowdin E, Cars O. The effects of protein binding on the phar-macodynamcis of tigecycline against Staphylococcus aureus and Escherichia coli. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; 2008 Oct 25-28; Washington, DC
21. Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006 Sep; 58 (3): 632-6
22. Gattringer R, Urbauer E, Traunmuller F, et al. Pharmacokinetics of teli-thromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother 2004 Dec; 48 (12): 4650-3
23. Rubino CM, Ma L, Bhavnani SM, et al. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharma-cokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother 2007 Nov; 51 (11): 4085-9
24. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007 Sep; 35 (9): 1543-53
25. Occhipinti DJ, Pendland SL, Schoonover LL, et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997 Nov; 41 (11): 2511-7
26. Bergan T, Engeset A, Olszewski W, et al. Extravascular penetration of highly protein-bound flucloxacillin. Antimicrob Agents Chemother 1986 Nov; 30 (5): 729-32
27. Pea F, Viale P, Pavan F, et al. Pharmacokinetic considerations for anti-microbial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46 (12): 997-1038
28. Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39 (3): 185-201
29. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992 Mar; 36 (3): 552-7
30. Nakayama I, Akieda Y, Yamaji E, et al. Single-and multiple-dose pharma-cokinetics of intravenous cefpirome (HR810) to healthy volunteers. J Clin Pharmacol 1992 Mar; 32 (3): 256-66
31. Mouton JW, Horrevorts AM, Mulder PG, et al. Pharmacokinetics of ceftazi-dime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990 Dec; 34 (12): 2307-11
32. Meyers BR, Srulevitch ES, Jacobson J, et al. Crossover study of the pharma-cokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother 1983 Nov; 24 (5): 812-4
33. Seddon M, Wise R, Gillett AP, et al. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother 1980 Aug; 18(2): 240-2
34. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000 May; 38 (5): 415-26
35. Winslade NE, Adelman MH, Evans EJ, et al. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Antimicrob Agents Chemother 1987 Apr; 31 (4): 605-9
36. Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on ami-noglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24 (5): 643-7
37. Traynor AM, Nafziger AN, Bertino Jr JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995 Feb; 39 (2): 545-8
38. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther 1985 Jun; 37 (6): 633-7
39. Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001 Jul; 45 (7): 2122-5
40. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997 Feb; 32 (2): 101-19
41. Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998 Aug; 42 (8): 2060-5
42. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ci-profloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000 Oct; 44 (10): 2600-3
43. Guay DR, Opsahl JA, McMahon FG, et al. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1992 Feb; 36 (2): 308-12
44. Lode H, Hoffken G, Olschewski P, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987 Sep; 31 (9): 1338-42
45. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992 Jun; 13 (6): 357-68
46. Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 1996 Jan-Feb; 18 (1): 56-72; discussion 55
47. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44 (9): 915-34
48. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007 Nov 15; 64 (22): 2335-48
49. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982 Apr; 21 (4): 575-80
50. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994 Oct; 16 (5): 513-8
51. MacGowan AP. Pharmacokinetic and pharmacodynamic profile oflinezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003 May; 51 Suppl. 2: ii17-25
52. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001 Aug; 29 (8): 1136-45
53. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64 (1): 63-88
54. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006 Dec; 58 (6): 1221-9
55. Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn?. J Antimicrob Chemother 2008 Feb; 61 (2): 235-7
56. Schwartz JB. The current state of knowledge on age, sex, and their inter-actions on clinical pharmacology. Clin Pharmacol Ther 2007 Jul; 82 (1): 87-96
57. Troy SM, Muralidharan G, Micalizzi M. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 13-17; Chicago (IL)
58. Rice PJ, Perry RJ, Afzal Z, et al. Antibacterial prescribing and warfarin: a review. Br Dent J 2003 Apr 26; 194 (8): 411-5
59. Raible DG, Zimmerman JJ, Harper DM, et al. Pharmacokinetics and phar-macodynamicsoftigecycline and warfarin coadministeredtohealthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
60. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005 Sep 1; 41 Suppl. 5: S341-53
61. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005 Sep 1; 41 Suppl. 5: S354-67
62. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Che-mother 2005 Jan; 49 (1): 220-9
63. Tombs NI. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)
64. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006 Aug; 58 (2): 256-65
65. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152, 288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000 Apr; 44 (4): 943-9
66. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003 Jan; 47 (1): 216-22
67. Testing-EUCAST TECoAS. Tetracyclines-EUCAST clinical MIC break-points 2008 June 19, version 2. 2 [online]. Available from URL: http:// www. srga. org/eucastwt/MICTAB/MICtetracyclines. htm [Accessed 2008 Dec 31]
68. Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003 Feb; 47 (2): 665-9
69. Nannini EC, Pai SR, Singh KV, et al. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003 Feb; 47 (2): 529-32
70. Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000 Nov; 44 (11): 3022-7
71. Yin LY, Lazzarini L, Li F, et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005 Jun; 55 (6): 995-1002
72. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline againstphenotypically diverse Staphylococcus aureusinamurine thigh model. Antimicrob Agents Chemother 2009 Dec; 53 (3): 1165-9
73. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1939-45
74. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008 Jan; 52 (1): 204-10
75. Burgess DS, Frei CR, Lewis Ii JS, et al. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect 2007 Jan; 13 (1): 33-9
76. Ambrose PG, Meagher AK, Passarell JA, et al. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline- Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 2009 Jan; 63 (1): 38-42